FDA Approves Expanded Liquid Biopsy Panel - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Expanded Liquid Biopsy Panel

Updated liquid biopsy combines genomic and epigenomic profiling for companion diagnostic use across multiple tumor types.

  • By

  • Kathryn Wighton

  • May 20, 2026

  • 2 min

Share

Objective:

To inform about the FDA approval of the Guardant360 Liquid CDx assay for advanced cancer treatment selection.

Key Findings:
  • The assay is the largest FDA-approved liquid biopsy panel.
  • It combines genomic and epigenomic profiling to improve tumor detection.
  • The platform is based on AI-enabled technology and supports various cancer care stages.
Interpretation:

This approval signifies a significant advancement in precision oncology, providing clinicians with timely and comprehensive information for treatment decisions.

Limitations:
  • The assay's effectiveness may vary based on individual patient factors.
  • Coverage by insurers may not be universal across all regions.
Conclusion:

The Guardant360 Liquid CDx assay represents a major step forward in liquid biopsy technology, potentially improving treatment outcomes for patients with advanced cancers.

Original Source(s)

FDA Approves Expanded Liquid Biopsy Panel

  • by Kathryn Wighton

  • May 20, 2026

Related Content

Urine Markers May Aid Psych Diagnosis

Genetically predicted urinary metabolite levels were associated with schizophrenia, bipolar disorder, attention-deficit/hyperactivity disorder, and anorexia nervosa in a Mendelian randomization analysis.

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

High-Dose Vitamin C Could Pose Risk in Severe Burns

“High-dose intravenous vitamin C administered early after injury did not reduce organ dysfunction or [mortality] and should not be a treatment in severe burns.”